Freestone Grove Partners LP Makes New Investment in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

Freestone Grove Partners LP purchased a new stake in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor purchased 30,313 shares of the biotechnology company's stock, valued at approximately $228,000.

Several other large investors also recently modified their holdings of BCRX. Venturi Wealth Management LLC bought a new position in shares of BioCryst Pharmaceuticals in the 4th quarter worth approximately $46,000. R Squared Ltd purchased a new position in BioCryst Pharmaceuticals during the fourth quarter valued at $48,000. KBC Group NV grew its holdings in BioCryst Pharmaceuticals by 80.1% during the fourth quarter. KBC Group NV now owns 10,198 shares of the biotechnology company's stock valued at $77,000 after purchasing an additional 4,537 shares during the period. Raymond James Financial Inc. bought a new position in shares of BioCryst Pharmaceuticals in the fourth quarter worth about $80,000. Finally, Syon Capital LLC purchased a new position in shares of BioCryst Pharmaceuticals during the 4th quarter valued at about $99,000. Institutional investors own 85.88% of the company's stock.

Analysts Set New Price Targets

A number of research firms have weighed in on BCRX. Wedbush started coverage on shares of BioCryst Pharmaceuticals in a research report on Tuesday, February 25th. They issued an "outperform" rating and a $15.00 price target for the company. Evercore ISI increased their price target on BioCryst Pharmaceuticals from $10.00 to $12.00 and gave the stock an "outperform" rating in a research note on Monday, January 13th. HC Wainwright restated a "buy" rating and issued a $30.00 price objective on shares of BioCryst Pharmaceuticals in a research report on Tuesday, February 25th. Cantor Fitzgerald initiated coverage on BioCryst Pharmaceuticals in a research report on Tuesday, April 29th. They set an "overweight" rating and a $20.00 target price for the company. Finally, JMP Securities restated a "market outperform" rating and issued a $18.00 price target on shares of BioCryst Pharmaceuticals in a research note on Friday, January 31st. One equities research analyst has rated the stock with a hold rating and eight have given a buy rating to the company's stock. According to MarketBeat, BioCryst Pharmaceuticals presently has an average rating of "Moderate Buy" and an average price target of $16.13.

BioCryst Pharmaceuticals Stock Performance

NASDAQ BCRX opened at $11.03 on Tuesday. The stock has a 50 day moving average price of $7.74 and a 200-day moving average price of $7.83. BioCryst Pharmaceuticals, Inc. has a one year low of $4.75 and a one year high of $11.11. The company has a market capitalization of $2.31 billion, a P/E ratio of -18.08 and a beta of 1.08.

BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) last announced its earnings results on Monday, May 5th. The biotechnology company reported $0.20 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.07) by $0.27. The company's quarterly revenue was up 56.8% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($0.17) EPS. As a group, equities analysts predict that BioCryst Pharmaceuticals, Inc. will post -0.36 EPS for the current fiscal year.

BioCryst Pharmaceuticals Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.